Amendments to the Specification

Please replace paragraph [0022] with the following amended paragraph:

[0022] The present invention relates to a method for treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of: (1) a compound having the formula



where Q is a group of the formula

$-CH_2-CH_2-$, $-CH=CH-$ or



,

R and R^1 are each independently C_1-C_4-alkyl, R_1 is thienyl, phenyl, cyclopentyl or cyclohexyl, and X^- is a physiologically acceptable anion; (2) a compound having the formula



where X^- is a physiologically acceptable ion; (3) a compound having the formula



where X^- is a physiologically acceptable ion; (4) a compound having the formula



,

where R_1 is 2-thienyl or cyclopentyl, and A is 3α-(6,7-dehydro)-tropanyl methobromide, 3β-tropanyl methobromide, or 3α-(N-isopropyl)-nortropanyl methobromide; (5) a compound having the formula



where R is an optionally halo- or hydroxyl-substituted C_{1-4} alkyl group, R^1 is a C_{1-4}-alkyl group, or R and R^1 together form a C_{4-6}-alkylene group, X^- is a physiologically acceptable anion, and R_1 is H, OH, CH_3, CH_2OH, C_{1-4} alkyl or C_{1-4}-alkoxy; (6) a compound having the formula



,

where R is an optionally halo- or hydroxy-substituted C_{1-4} –alkyl group, R^1 is a C_{1-4} –alkyl group, or R and R^1 together form a C_{4-6}- alkylene group, X^- is a physiologically acceptable anion and R_1 is H, OH, CH_3, CH_2OH, C_{1-4} –alkyl or C_{1-4} –alkoxy; (7) a compound having the formula



;

(8) a compound having the formula





;

and (9) a compound having the formula



where X^- is a physiologically acceptable anion.

Please replace paragraph [0024] with the following amended paragraph:

[0024] The present invention relates to a method for treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of: a compound having the formula



where Q is a group of the formula

$-CH_2-CH_2-$, $-CH=CH-$ or



,

R and R^1 are each independently C_1-C_4-alkyl, R_1 is thienyl, phenyl, cyclopentyl or cyclohexyl, and X^- is a physiologically acceptable anion. In this aspect and all aspects of the present invention, R may be, without limitation, CH_3, C_2H_5, n-C_3H_7, or i-C_3H_7; R^1 may be, without limitation, CH_3, and X^- is meant to include, without limitation, bromide (Br^-) and CH_3SO_3.

Please replace paragraph [0031] with the following amended paragraph:

[0031] In another aspect of the present invention, treatment of a bladder disease involves administering to a subject a compound having the formula





.

Please replace paragraph [0032] with the following amended paragraph:

[0032] In another aspect of the present invention, treatment of a bladder disease involves administering to a subject a compound having the formula



where X^- is a physiologically acceptable ion as described herein above.